SCHEMBL14877975

SCHEMBL14877975

CCCCCCCCCCCCCCCCCCOCC(COC)OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 9/20 0.62
LPAR3 Q9UBY5 9/20 0.62
LPAR2 Q9HBW0 6/20 0.62
LPAR6 P43657 5/20 0.57
LPAR4 Q99677 5/20 0.57
LPAR5 Q9H1C0 5/20 0.57
USP2 O75604 1/20 0.55
DNM1 Q05193 1/20 0.53
PRKD3 O94806 1/20 0.51
PRKCG P05129 1/20 0.51
PRKCB P05771 1/20 0.51
PRKCA P17252 1/20 0.51
PRKCH P24723 1/20 0.51
PRKCI P41743 1/20 0.51
PRKCE Q02156 1/20 0.51
PRKCQ Q04759 1/20 0.51
PRKCZ Q05513 1/20 0.51
PRKCD Q05655 1/20 0.51
PRKD1 Q15139 1/20 0.51
TLR2 O60603 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15158747 1.00 LPAR1 (0.62) LPAR1LPAR3LPAR2LPAR6LPAR4
SCHEMBL19829619 1.00 LPAR1 (0.62) LPAR1LPAR3LPAR2LPAR6LPAR4
SCHEMBL16303701 1.00 LPAR1 (0.62) LPAR1LPAR3LPAR2LPAR6LPAR4
SCHEMBL13659941 1.00 LPAR1 (0.62) LPAR1LPAR3LPAR2LPAR6LPAR4
SCHEMBL4294185 0.94 LPAR1 (0.68) LPAR1LPAR3LPAR2LPAR6LPAR4
SCHEMBL8636551 0.94 LPAR1 (0.68) LPAR1LPAR3LPAR2LPAR6LPAR4
SCHEMBL7563995 0.94 LPAR1 (0.68) LPAR1LPAR3LPAR2LPAR6LPAR4
SCHEMBL4879843 0.94 LPAR1 (0.68) LPAR1LPAR3LPAR2LPAR6LPAR4
SCHEMBL303128 0.94 LPAR1 (0.68) LPAR1LPAR3LPAR2LPAR6LPAR4
SCHEMBL4204833 0.94 LPAR1 (0.68) LPAR1LPAR3LPAR2LPAR6LPAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9814777-B2 Targeting lipids ARBUTUS BIOPHARMA CORPORATION (CA) 2017-11-14 US disclosed
EP-3156077-A1 TARGETING LIPIDS Arbutus Biopharma Corporation (CA) 2017-04-19 EP disclosed
EP-2231195-B1 TARGETING LIPIDS ARBUTUS BIOPHARMA CORP (CA) 2017-03-29 EP disclosed
US-20160376591-A1 iRNA AGENTS WITH BIOCLEAVABLE TETHERS BANK OF AMERICA, N.A. 2016-12-29 US disclosed
US-9476045-B2 iRNA agents with biocleavable tethers ALNYLAM PHARMACEUTICALS, INC. (US) 2016-10-25 US disclosed
US-20150073133-A1 iRNA AGENTS WITH BIOCLEAVABLE TETHERS BANK OF AMERICA, N.A. 2015-03-12 US disclosed
US-8865677-B2 iRNA agents with biocleavable tethers ALNYLAM PHARMACEUTICALS, INC. (US) 2014-10-21 US disclosed
US-20140179761-A1 TARGETING LIPIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2014-06-26 US disclosed
US-20130281685-A1 iRNA AGENTS WITH BIOCLEAVABLE TETHERS BANK OF AMERICA, N.A. 2013-10-24 US disclosed
US-8426377-B2 iRNA agents with biocleavable tethers ALNYLAM PHARMACEUTICALS, INC. (US) 2013-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179761-A1 TARGETING LIPIDS LY96, ABHD10, APOB LPAR1 4/4885LPAR3 16/4885LPAR2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.